RT Journal Article
SR Electronic
T1 Translationally Controlled Tumor Protein <em>TCTP</em> as Peptide Vaccine against <em>Schistosoma japonicum</em>: an Immunoinformatics Approach
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 466847
DO 10.1101/466847
A1 Rayan A Abdalrahman
A1 Shima S Ahmed
A1 Mahmoud A Elnaeem
A1 Marwa S Mohammed
A1 Nawraz M Jammie
A1 Israa A Yousif
A1 Wala H Mohamed
A1 Sabreen Y Nasr
A1 Mawadda A Awad-Elkareem
A1 Mohamed A Hassan
YR 2019
UL http://biorxiv.org/content/early/2019/01/28/466847.abstract
AB Schistosoma japonicum is the most pathogenic causative form of schistosomiasis that causes a major health problem in its endemic countries. Until now, praziquantel is the only drug used to treat Schistosomiasis, but it does not prevent re-infection. So, repetition of the treatment is needed. Moreover, there is no effective vaccine against S. japonicum. Therefore, an urgent need for the development of vaccines is mandatory. This study aimed to analyze an immunogenic protein, Transitionally Controlled Tumor Protein (TCTP) using an immunoinformatics approach to design a universal peptide vaccine against Schistosoma japonicum. A set of 22 of TCTP sequences were retrieved from NCBI database. Conservancy of these sequences was tested and then conserved B cell and T cell epitopes were predicted using different tools available in IEBD. Epitopes having high scores in both B and T cell predicting tools were proposed. An epitope 129YEHYI133 was predicted as a most promising epitope with good prediction scores in surface accessibility and antigenicity. Besides that, epitopes 129YEHYIGESM 137and 92YLKAIKERL100 were predicted as the most promising epitopes concerning their binding to MHC I and MHC II allele respectively. The study revealed that our predicted epitopes could be used to develop an efficacious vaccine against Schistosoma japonicum in the future especially epitope YEHYIGESM as it is shared between MHC I and II alleles and overlapped with the most promising B cell epitope. Both in vitro and in vivo studies is recommended to confirm the efficacy of YEHYIGESM as a peptide vaccine.